Does Cosentyx Affect Infant Development During Pregnancy?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, lacks large-scale human data on pregnancy outcomes. Animal studies show no direct harm to fetal development at doses up to 50 times human levels—no malformations or growth issues observed. Human evidence is limited to case reports and registries like the European Psoriasis Pregnancy Study, where exposed infants showed normal development, though sample sizes are small (under 100 cases). No confirmed signals of developmental delays, cognitive issues, or congenital anomalies link to Cosentyx use.[1][2]
What Do Pregnancy Registries Show?
The OTIS Autoimmune Diseases in Pregnancy registry tracked 60 women on secukinumab; rates of major malformations (3.3%) matched unexposed controls (2.9%), with no infant developmental concerns at 12 months. The MotherToBaby study similarly found no increased risks for miscarriage, preterm birth, or low birth weight. Long-term neurodevelopment data remains absent, as most exposures are recent.[3][4]
How Does It Cross the Placenta?
Secukinumab crosses the placenta minimally in the first trimester but substantially after week 24, leading to detectable levels in newborns (up to 25% of maternal concentration). This raises potential immunosuppression risks for infants, like higher infection susceptibility in the first months, but no direct developmental impacts reported.[1][5]
What Risks Do Breastfeeding Infants Face?
Infant serum levels drop to undetectable by 12-16 weeks postpartum. No adverse developmental effects noted in breastfed infants, though monitoring for infections is advised. Short-term breastfeeding appears safe.[2][6]
When Is It Used Safely in Pregnancy?
Most data involves second- or third-trimester use for maternal conditions. First-trimester avoidance is common due to limited info, but continuation often outweighs risks for severe disease. ACOG and FDA classify it as Pregnancy Category B (no human risk evidence, animal safety).[1][7]
What Alternatives Exist for Pregnant Patients?
TNF inhibitors like etanercept or adalimumab have more pregnancy data and similar safety profiles—no developmental risks confirmed. Topical therapies or methotrexate (contraindicated in pregnancy) serve milder cases. Decisions hinge on disease severity.[4][8]
[1]: Novartis Cosentyx Prescribing Information
[2]: Drugs in Pregnancy and Lactation Database
[3]: OTIS Registry Data
[4]: MotherToBaby Fact Sheet: Secukinumab
[5]: FDA Pregnancy and Lactation Labeling Rule Summary
[6]: AAP Breastfeeding Guidelines
[7]: ACOG Immunosuppressants in Pregnancy
[8]: DrugPatentWatch.com - Secukinumab Patents